Table I.
Patient, donor and transplant characteristics of the study population
| Variable | N(%)(n= 24,963) |
|---|---|
| Recipient factors | |
| Age | |
| 18-29 | 2,220 (8.89) |
| 30-44 | 7,395 (29.62) |
| 45-59 | 9,801 (39.26) |
| 60+ | 5,547 (22.22) |
| Female gender | 9,703 (38.87) |
| Racial background | |
| Black | 8,764 (35.11) |
| Other | 1,621 (6.49) |
| White | 14,578 (58.4) |
| Hispanic origin | 3,248 (13.01) |
| Body mass index | |
| Normal | 10,699 (42.86) |
| Overweight | 7,895 (31.63) |
| Obese | 5,523 (22.12) |
| Unknown | 846 (3.39) |
| Limits | 2,103 (8.42) |
| Primary cause of ESRD | |
| Type I diabetes | 2,938 (11.77) |
| Type II diabetes | 3,803 (15.23) |
| Hypertension | 6,310 (25.28) |
| Polycystic kidney disease (PKD) | 1,819 (7.29) |
| Glomeruloneprhitis | 4,751 (19.03) |
| Other | 3,090 (12.38) |
| Unknown | 2,252 (9.02) |
| Pre-tx-dialysis duration | |
| 12-24 months | 4,472 (17.91) |
| 24-60 months | 14,612 (58.53) |
| > 60 months | 5,879 (23.55) |
| OPTN recorded comorbidities | |
| Angina | 3,182 (12.75) |
| Arrhythmia | 184 (0.74) |
| Congestive heart failure | 1,685 (6.75) |
| COPD | 427 (1.71) |
| Cerebrovascular disease | 609 (2.44) |
| Myocardial infarction | 342 (1.37) |
| Diabetes | 7,607 (30.47) |
| Peripheral vascular disease | 1,560 (6.25) |
| Smoking history | 703 (2.82) |
| Alcohol abuse history | 144 (0.58) |
| Donor factors | |
| Age | |
| < 18 | 3,795 (15.2) |
| 18-29 | 4,797 (19.22) |
| 30-44 | 5,354 (21.45) |
| 45-59 | 5,808 (23.27) |
| 60+ | 2,042 (8.18) |
| Unknown | 3,167 (12.69) |
| Female gender | 9,968 (39.93) |
| Racial background | |
| Black | 3,031 (12.14) |
| Other | 1,421 (5.69) |
| White | 20,511 (82.17) |
| Hispanic origin | 2,709 (10.85) |
| Body mass index | |
| Normal | 12,747 (51.06) |
| Overweight | 6,506 (26.06) |
| Obese | 4,831 (19.35) |
| Unknown | 879 (3.52) |
| Donor cause of death | |
| Anoxia | 2,291 (9.18) |
| Cerebrovascular/stroke | 9,789 (39.21) |
| Head trauma | 11,448 (45.86) |
| CNS tumor | 250 (1) |
| Other | 1,185 (4.75) |
| Donor comorbidities | |
| Hypertension | 4,744 (19.0) |
| Diabetes | 855 (3.43) |
| Alcohol abuse | 4,539 (18.18) |
| Cigarette use | 9,344 (37.43) |
| Drug use | 4,382 (17.55) |
| Transplant characteristics | |
| PRA ≥ 50% | 1,366 (5.47) |
| HLA mismatches | |
| No MM | 1,982 (7.94) |
| No DR MM | 5,609 (22.47) |
| DR MM | 17,372 (69.59) |
| Cold ischemia time | |
| 0-12 h | 3,418 (13.69) |
| 13-24 h | 11,991 (48.04) |
| 25-36 h | 6,288 (25.19) |
| 36+ h | 1,014 (4.06) |
| Undetermined | 2,252 (9.02) |
| Charlson comorbidities | |
| 0 | 6,302 (25.25) |
| 1 | 7,446 (29.83) |
| 2 | 4,938 (19.78) |
| 3 | 3,298 (13.21) |
| 4 | 1,839 (7.37) |
| 5 | 793 (3.18) |
| 6 or more | 347 (1.39) |
| Elixhauser comorbidities | |
| 0 | 4,481 (17.95) |
| 1 | 3,294 (13.2) |
| 2 | 3,453 (13.83) |
| 3 | 3,415 (13.68) |
| 4 | 2,929 (11.73) |
| 5 | 2,411 (9.66) |
| 6 | 1,891 (7.58) |
| 7 | 1,302 (5.22) |
| 8 | 869 (3.48) |
| 9 | 479 (1.92) |
| 10 | 249 (1) |
| 11 or more | 190 (0.76) |
| Cytomegalovirus sero-pairing | |
| Donor–/recipient– | 2,892 (11.59) |
| Donor–/recipient≥ | 5,468 (21.9) |
| Donor≥/recipient– | 4,150 (16.62) |
| Donor≥/recipient≥ | 9,680 (38.78) |
| Undiagnosed | 2,773 (11.11) |
| Delayed graft function | 9,626 (38.56) |
| Induction immunosupression | 12,026 (48.18) |
| Discharge immunosupression (ref = tacrolimus and MMF) | |
| Cyclosporine and MMF | 9,009 (36.09) |
| Cyclosporine and azathioprine | 3,638 (14.57) |
| Tacrolimus and MMF | 6,066 (24.3) |
| Other | 6,250 (25.04) |
| Steroid Use | 23,339 (93.49) |